{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:13:29Z","timestamp":1790435609135,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"\n Purpose:<\/jats:title>\n To evaluate the morphometric changes in macular neovascularization (MNV) architecture after faricimab treatment in neovascular age-related macular degeneration, comparing treatment-naive and previously treated eyes.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Prospective study analyzing 45 eyes (18 treatment naive, 27 switched) with neovascular age-related macular degeneration undergoing faricimab treatment. Optical coherence tomography angiography images were exported and the quantification of changes in MNV area, vessel area, vessel density, number of junctions, branching index, total vessel length, end points, and lacunarity was performed using AngioTool v0.6a. Follow-ups at baseline (V0), at the end of the loading phase (V1), and at 1 year (V2) were collected.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Baseline MNV characteristics differed significantly between treatment-naive and switched eyes. Switched eyes exhibited greater MNV area (\n P<\/jats:italic>\n < 0.001), vessel area (\n P<\/jats:italic>\n < 0.001), junction count (\n P<\/jats:italic>\n = 0.004), vessel length (\n P<\/jats:italic>\n < 0.001), average vessel length (\n P<\/jats:italic>\n = 0.02), end point count (\n P<\/jats:italic>\n = 0.002), and lacunarity (\n P<\/jats:italic>\n = 0.04). Conversely, naive eyes had higher vessel density (\n P<\/jats:italic>\n < 0.001) and branching index (\n P<\/jats:italic>\n = 0.007). Posttreatment, MNV area (\n P<\/jats:italic>\n < 0.001), vessel area (\n P<\/jats:italic>\n < 0.001), junction count (\n P<\/jats:italic>\n = 0.001), and total vessel length (\n P<\/jats:italic>\n < 0.001) decreased, whereas lacunarity increased (\n P<\/jats:italic>\n = 0.001). Greater changes were observed in naive eyes, but the end point count only reduced in switched eyes (\n P<\/jats:italic>\n = 0.01), being stable in naive eyes. At V2, switched eyes still had larger MNV area (\n P<\/jats:italic>\n = 0.007), vessel area (\n P<\/jats:italic>\n = 0.004), junction count (\n P<\/jats:italic>\n = 0.002), vessel length (\n P<\/jats:italic>\n = 0.004), and end points (\n P<\/jats:italic>\n = 0.007).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Faricimab induces significant and sustained remodeling of the MNV network in neovascular age-related macular degeneration, with more pronounced changes in treatment-naive eyes. These changes were primarily driven by the loading phase, but then remained stable toward the 1-year follow-up.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/iae.0000000000004635","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T21:01:57Z","timestamp":1755118917000},"page":"125-135","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["MORPHOMETRIC CHANGES IN MACULAR NEOVASCULARIZATION ARCHITECTURE AFTER FARICIMAB TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-1638","authenticated-orcid":false,"given":"Matteo M.","family":"Carl\u00e0","sequence":"first","affiliation":[{"name":"Ophthalmology Department, Catholic University \u201cSacro Cuore\u201d, Rome, Italy;"},{"name":"Vitreoretinal Surgery Unit, Isola Tiberina Hospital-Gemelli Isola, Rome, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Scampoli","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, \u201cFondazione Policlinico Universitario A. Gemelli, IRCCS\u201d, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Grieco","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Catholic University \u201cSacro Cuore\u201d, Rome, Italy;"},{"name":"Vitreoretinal Surgery Unit, Isola Tiberina Hospital-Gemelli Isola, Rome, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Governatori","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, \u201cFondazione Policlinico Universitario A. Gemelli, IRCCS\u201d, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Catalani","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, \u201cFondazione Policlinico Universitario A. Gemelli, IRCCS\u201d, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislao","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Catholic University \u201cSacro Cuore\u201d, Rome, Italy;"},{"name":"Vitreoretinal Surgery Unit, Isola Tiberina Hospital-Gemelli Isola, Rome, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomaso","family":"Caporossi","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Catholic University \u201cSacro Cuore\u201d, Rome, Italy;"},{"name":"Ophthalmology Department, \u201cFondazione Policlinico Universitario A. Gemelli, IRCCS\u201d, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251218","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng","year":"2022","journal-title":"Genes Dis"},{"key":"R2-20251218","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R3-20251218","doi-asserted-by":"crossref","first-page":"100825","DOI":"10.1016\/j.preteyeres.2019.100825","article-title":"Age-related macular degeneration: a two-level model hypothesis","volume":"76","author":"Rozing","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"R4-20251218","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/aos.13187","article-title":"Reduced occurrence of severe visual impairment after introduction of anti-vascular endothelial growth factor in wet age-related macular degeneration-a population- and register-based study from northern Sweden","volume":"94","author":"Granstam","year":"2016","journal-title":"Acta Ophthalmologica"},{"key":"R5-20251218","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010","volume":"153","author":"Bloch","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R6-20251218","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"Tenaya and lucerne: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"R7-20251218","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","article-title":"Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME","volume":"10","author":"Penha","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"R8-20251218","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s40123-024-00980-5","article-title":"Real-world outcomes of a loading phase with intravitreal faricimab in neovascular age-related macular degeneration (n-AMD) and diabetic macular edema (DME)","volume":"13","author":"Giancipoli","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"R9-20251218","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40942-024-00586-w","article-title":"Intravitreal faricimab for treatment naive patients with neovascular age-related macular degeneration: a real-world prospective study","volume":"10","author":"Grimaldi","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"R10-20251218","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10384-023-01040-4","article-title":"One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naive neovascular age-related macular degeneration","volume":"68","author":"Matsumoto","year":"2024","journal-title":"Jpn J Ophthalmol"},{"key":"R11-20251218","doi-asserted-by":"crossref","first-page":"11681","DOI":"10.1038\/s41598-024-62559-1","article-title":"One-year outcomes and safety assessment of faricimab in treatment-na\u00efve patients with neovascular age-related macular degeneration in Japan","volume":"14","author":"Mukai","year":"2024","journal-title":"Scientific Rep"},{"key":"R12-20251218","doi-asserted-by":"crossref","first-page":"100049","DOI":"10.1016\/j.ajoint.2024.100049","article-title":"Short-term results with faricimab in neovascular age-related macular degeneration resistant to both ranibizumab and aflibercept","volume":"1","author":"Schneider","year":"2024","journal-title":"AJO Int"},{"key":"R13-20251218","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.2147\/OPTH.S482948","article-title":"Real-world-data of treatment-naive and previously treated patients receiving up to 3 injections of faricimab in neovascular age-related macular degeneration","volume":"18","author":"Kunzmann","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"R14-20251218","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","article-title":"Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema","volume":"38","author":"Borchert","year":"2024","journal-title":"Eye (Lond)"},{"key":"R15-20251218","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2147\/OPTH.S424315","article-title":"One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration","volume":"17","author":"Rush","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"R16-20251218","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1111\/aos.14554","article-title":"Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA","volume":"99","author":"Told","year":"2021","journal-title":"Acta Ophthalmologica"},{"key":"R17-20251218","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/02713683.2020.1849734","article-title":"Correlation of retinal thickness and swept-source optical coherence tomography angiography derived vascular changes in patients with neovascular age-related macular degeneration","volume":"46","author":"Told","year":"2021","journal-title":"Curr Eye Res"},{"key":"R18-20251218","first-page":"34","article-title":"Predictive role of optical coherence tomography angiography for exudation recurrence in patients with type 1 neovascular age-related macular degeneration treated with pro-re-nata protocol","volume":"37","author":"Choi","year":"2023","journal-title":"Eye (Basingstoke)"},{"key":"R19-20251218","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000487611","article-title":"Optical coherence tomography angiography to quantify choroidal neovascularization in response to aflibercept","volume":"240","author":"Takeuchi","year":"2018","journal-title":"Ophthalmologica"},{"key":"R20-20251218","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000503609","article-title":"Assessment of exudative activity of choroidal neovascularization in age-related macular degeneration by OCT angiography","volume":"243","author":"Von Der Emde","year":"2020","journal-title":"Ophthalmologica"},{"key":"R21-20251218","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/tvst.9.3.18","article-title":"Quantitative optical coherence tomography angiography biomarkers in a treat-and-extend dosing regimen in neovascular age-related macular degeneration","volume":"9","author":"Cabral","year":"2020","journal-title":"Translational Vis Sci Technol"},{"key":"R22-20251218","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/jcm10040751","article-title":"Optical coherence tomography angiography of the choriocapillaris in age-related macular degeneration","volume":"10","author":"Scharf","year":"2021","journal-title":"J Clin Med"},{"key":"R23-20251218","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/IAE.0000000000001628","article-title":"Biomarkers of neovascular activity in age-related macular degeneration using optical coherence tomography angiography","volume":"38","author":"Al-Sheikh","year":"2018","journal-title":"Retina"},{"key":"R24-20251218","doi-asserted-by":"crossref","first-page":"e0205513","DOI":"10.1371\/journal.pone.0205513","article-title":"Quantitative optical coherence tomography angiography biomarkers for neovascular agerelated macular degeneration in remission","volume":"13","author":"Coscas","year":"2018","journal-title":"PLoS One"},{"key":"R25-20251218","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaophthalmol.2016.4272","article-title":"Visualization of 3 distinct retinal plexuses by projection-resolved optical coherence tomography angiography in diabetic retinopathy","volume":"134","author":"Hwang","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R26-20251218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","article-title":"Optical coherence tomography angiography","volume":"64","author":"Spaide","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R27-20251218","doi-asserted-by":"crossref","first-page":"e27385","DOI":"10.1371\/journal.pone.0027385","article-title":"A computational tool for quantitative analysis of vascular networks","volume":"6","author":"Zudaire","year":"2011","journal-title":"PLoS One"},{"key":"R28-20251218","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mvr.2018.02.006","article-title":"Fractal dimension and lacunarity analysis of retinal microvascular morphology in hypertension and diabetes","volume":"118","author":"Popovic","year":"2018","journal-title":"Microvasc Res"},{"key":"R29-20251218","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/IAE.0000000000001400","article-title":"Semiautomated quantitative approach to characterize treatment response in neovascular age-related macular degeneration: a Real-World Study","volume":"37","author":"Roberts","year":"2017","journal-title":"Retina"},{"key":"R30-20251218","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41433-023-02574-0","article-title":"Quantitative response of macular neovascularisation to loading phase of aflibercept in neovascular age-related macular degeneration","volume":"37","author":"Montesel","year":"2023","journal-title":"Eye (Lond)"},{"key":"R31-20251218","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1097\/IAE.0000000000000879","article-title":"Longitudinal optical coherence tomography-angiography study of type 2 naive choroidal neovascularization early response after treatment","volume":"35","author":"Lumbroso","year":"2015","journal-title":"Retina"},{"key":"R32-20251218","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000442782","article-title":"Optical coherence tomography angiography study of choroidal neovascularization early response after treatment","volume":"56","author":"Lumbroso","year":"2016","journal-title":"Dev Ophthalmol"},{"key":"R33-20251218","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajo.2017.12.005","article-title":"Long-term progression of type 1 neovascularization in age-related macular degeneration using optical coherence tomography angiography","volume":"187","author":"Xu","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R34-20251218","article-title":"Long\u2010term follow up of macular neovascularization using optical coherence tomography angiography: pro Re Nata versus Treat&Extend regimens Conference poster: 124\u2010A0305","author":"Sustronck","year":"2019","journal-title":"ARVO"},{"key":"R35-20251218","doi-asserted-by":"crossref","first-page":"36992","DOI":"10.1038\/srep36992","article-title":"Effects of endothelial cell proliferation and migration rates in a computational model of sprouting angiogenesis","volume":"6","author":"Norton","year":"2016","journal-title":"Scientific Rep"},{"key":"R36-20251218","first-page":"1116","article-title":"Morphologic observations on experimental subretinal neovascularization in the monkey","volume":"28","author":"Ishibashi","year":"1987","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R37-20251218","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2015.04.012","article-title":"Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization","volume":"160","author":"Spaide","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R38-20251218","first-page":"3365","article-title":"The relationship between vascular maturation and anti-angiogenic therapy resistance in neovascular AMD","volume":"61","author":"Stattin","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R39-20251218","first-page":"193","article-title":"Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration","volume":"14","author":"Ng","year":"2024","journal-title":"Life (Basel)"},{"key":"R40-20251218","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1167\/iovs.65.11.32","article-title":"Quantitative evaluation of type 1 and type 2 choroidal neovascularization components under treatment with projection-resolved OCT angiography","volume":"65","author":"Tsuboi","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:01:18Z","timestamp":1766073678000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004635"}},"subtitle":["Comparison Between Naive and Switched Eyes"],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004635","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}